Hospital Bribery Continues In Asia Despite Increased Enforcement
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - The use of bribery as a standard business practice in Asia remains a concern for pharma industry observers, despite the fact that more countries are actively enforcing international anti-bribery conventions
You may also be interested in...
China's Ministry Of Health To Expand Corruption Probe In Pharma Sector
BEIJING - Investors in China-based pharmaceutical firms have been so rattled by a widening government probe into potentially improper payments to regulators and doctors, and by the review of drug price levels for possible state-mandated cuts, that they have begun selling off equity stakes in those firms, according to a prominent analyst who closely follows China's healthcare sector from Merrill Lynch's office in Hong Kong
Korea's Trade Commission Offers Payment To Whistleblowers Reporting Rebates
SEOUL - In its latest anti-rebate move, South Korea's Fair Trade Commission is offering up to KRW100 million ($82,440) to whistleblowers who uncover illegal rebates offered by pharma companies for sales of their products to hospitals. The new punitive system took effect June 17
Vietnamese Press Reports Accusations That U.S. Drug Firm Paid Illicit Commissions To Doctors
SHANGHAI - A local newspaper in Vietnam has reported that doctors at a public hospital are suspected of having taken illicit commissions to prescribe drugs made by the U.S. pharmaceutical company Schering-Plough